Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: Results from a randomized trial

Onkologie

Volumn 25, Issue 6, 2002, Pages 503-508

  Mross, Klaus ^a   Haring B ^a   Hollander N ^a   Mielke, S ^b   Behringer, D ^b   Massing, U ^a   Unger, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

1 and 3h application; Paclitaxel; Pharmacokinetics; Randomized study

Indexed keywords

PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; FEMALE; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MALE; MEAN RESIDENCE TIME; NEUROTOXICITY; NEUTROPHILIA; OVARY CANCER; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LIVER FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; PACLITAXEL;

EID: 0036983328     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068620     Document Type: Article

References (33)

1. Rosenthal DI, Lee JH, Sinard R, Yardley DA, Machtay M, Rosen DM, Egorin MJ, Weber RS, Weinstein GS, Chalian AA, Miller LK, Frenkel EP, Carbone DP: Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-1373.
2. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 1992;10:275-278.
3. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, O'Shoughnessy JA: Pharmacokinetics of Taxol and Doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994;86:143-145.
4. Wiernick PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of Taxol given as 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-1239.
5. Wiernick PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical trial and pharmacokinetic study of Taxol. Cancer Res 1987;47:2486-2493.
6. Seidman AD, Tiersten A, Hudis C, Gollup M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Skalrin N, Moynikan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
7. Hainsworth JD, Greco FA: Paclitaxel administered by 1-hour infusion. Cancer 1994;74:1377-1382.
8. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC: Phase I study of taxol administered as a short intravenous infusion daily for 5 days. Cancer Treat Rep 1987;71:1179-1181.
9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
10. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995;13:1609-1614.
11. Greco FA, Hainsworth JD: Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: Results of a multicenter phase II study. Sem Oncol 1997;24:S12-14-S12-17.
12. Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H: Clinical phase I study with one-hour infusion. Ann Oncol 1998;9:569-572.
13. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonodonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 1995;13:180-190.
14. Kearns CM, Gianni L, Egorin M: Paclitaxel pharmacokinetics and pharmacodynamics. Sem Oncol 1995;22(suppl 6):16-23.
15. Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-2135.
16. Mross K, Holländer N, Hauns B, Schumacher M, Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000;45:463-470.
17. D'Addario G, Morant R, Böhme C, Cerny T: Feasibility and toxicity of weekly paclitaxel-carboplatin in 131 patients pretreated and non-pretreated solid tumors. Onkologie 2002;25:152-157.
18. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-2369.
19. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH: High performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 1993;621:231-238.
20. Wagner JG, Searle JG: Pharmacokinetics for the Pharmacoceutical Scientist. Lancaster, Technomic Publ, 1993.
21. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, ed 3. Philadelphia, Lea and Febiger, 1984.
22. Bailer AJ, Piegorsch WW: Estimating integrals using quadrature methods with an application in pharmacokinetics. Biometrics 1980;46:1201-1211.
23. Gurney HP, Ackland S, Gebsk V, Farell G: Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculations. J Clin Oncol 1998;16:2299-2304.
24. SAS Institute Inc., SAS/STAT user's guide. Version 6, ed 4. NC, SAS Institute Inc., 1989.
25. Philip H, Schwartz CP: The application of BASE SAS, SAS/STAT, and SAS/GRAPH software to the analysis and presentation of pharmacokinetic data. Proceedings of the SAS User's Group International Conference 1989;14:1168-1172.
26. Gelderblom H, Mross K, ten Tije A, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 2002;20:574-581.
27. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Et-tinger DS, Donehower RC: Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 1989;49:4640-4647.
28. 2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother Pharmacol 2001;47:45-50.
29. Weiss R, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, van Echo DA, von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
30. Tsavaris NB, Kosmas C: Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 1998;42:509-511.
31. Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM, Beijnen JH: Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann Oncol 1995;6:699-704.
32. Mielke S, Mross K, Glocker FX, Unger C, Behringer D: Neurotoxicty of paclitaxel infused weekly over one versus three hours: Preliminray results of a phase III trial. Proceedings ASCO 2001;20:107a.
33. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, Veenhoff CHN, Vermorken JB, Giaccone G, Pinedo HM: Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Sem Oncol 1994;21:53-62.